Why choose TREMFYA®?
In clinical trials of patients who received TREMFYA® IV initial and SC maintenance dosing, TREMFYA® helped patients achieve:
FAST ACTING
Rapid symptom relief*
at 4 weeks
and clinical remission
at week 12.
*Symptom relief is based on fewer bowel movements and less rectal bleeding (bloody stools) observed as early as week 4.
LONG LASTING
Clinical remission at
1 year.†
†Results were measured in TREMFYA® patients who met clinical response at 12 weeks.
VISIBLE REPAIR
OF THE INTESTINAL LINING
OF THE INTESTINAL LINING
Endoscopic remission
at 1 year.‡§
‡Visually assessed areas may
not represent remission of the
entire colon lining.
§Results were measured in TREMFYA® patients who met clinical response at
12 weeks.
AT 2 YEARS,
AT 2 YEARS,
patients were in clinical remission.ǁ
ǁIn UC, results at 1 and 2 years were measured in TREMFYA® patients who met clinical response at 12 weeks. After 1 year, patients and doctors knew TREMFYA® was used. This may have influenced results.
Results may vary.
Talk to your healthcare provider to
see if TREMFYA® is right for you.
TREMFYA® is the only IL-23 blocker for UC to offer self-administration from the start
You and your healthcare provider will discuss how you start TREMFYA® for UC:
Subcutaneous (SC) injections under the skin following training*
OR
IV infusions through
a vein in the arm
*If your healthcare provider decides that you or a caregiver may be able to give your injections of TREMFYA® at home, you should receive training on the right way to prepare and inject TREMFYA®. Do not try to inject yourself until you have been trained by your healthcare provider.
IL=interleukin.
